Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.

  title={Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.},
  author={Matthew E. Falagas and Sofia K. Kasiakou},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  volume={40 9},
  • M. Falagas, S. Kasiakou
  • Published 1 May 2005
  • Biology, Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
The emergence of multidrug-resistant gram-negative bacteria and the lack of new antibiotics to combat them have led to the revival of polymyxins, an old class of cationic, cyclic polypeptide antibiotics. Polymyxin B and polymyxin E (colistin) are the 2 polymyxins used in clinical practice. Most of the reintroduction of polymyxins during the last few years is related to colistin. The polymyxins are active against selected gram-negative bacteria, including Acinetobacter species, Pseudomonas… 

Figures and Tables from this paper

Polymyxins A Word of Caution for Prudent Use of Valuable “Old Antibiotics”

There is an urgent need for restriction of polymyxin use, to decrease the rate of emergence of really pandrug-resistant gram-negative bacteria—that is, bacteria with in vitro resistance to b-lactams, quinolones, aminoglycosides, tetracyclines, andpolymyxins.

Polymyxin antibiotics for gram-negative infections.

  • T. ArnoldG. ForrestKaren J Messmer
  • Medicine, Biology
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2007
The polymyxins seem to be effective in treating various infections caused by multidrug-resistant gram-negative organisms but should not be used as first-line therapy until more is known about this class of antibiotics.

Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.

Since polymyxins will be increasingly used for the treatment of infections caused by MDR bacteria, clinical pharmacokinetic, pharmacodynamic and toxicodynamic studies underpinning the optimal use of these drugs are urgently required.

Review Colistin, mechanisms and prevalence of resistance

This review concentrates on recent literature aimed at optimizing the clinical use of colistin, focusing on its chemistry, antibacterial activity, mechanism of action and resistance, pharmacokinetics, pharmacodynamics and new clinical application.

Colistin, mechanisms and prevalence of resistance

There is a critical need for effective infection prevention and control measures and strict use of antibiotics in the world to control the rise and spread of colistin resistance.

Intravenous colistin in the treatment of multidrug-resistant gram-negative organism in tertiary hospital, Jazan, KSA

It was showed that IV colistin treatment against the multidrug-resistant bacteria (gram-negative bacteria) was strongly related to mild nephrotoxicity in addition to with a proper response as shown only in three of the authors' patients.

Intravenous colistin sulfate: A rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections

In conclusion, intravenous colistin sulfate is a safe and viable alternative for the treatment of severe infections due to sensitive MDR Gram-negative bacteria.

Toxicity of polymyxins: a systematic review of the evidence from old and recent studies

New evidence shows that polymyxins have less toxicity than previously reported, and the avoidance of concurrent administration of nephrotoxic and/or neurotoxic drugs, careful dosing, as well as more meticulous management of fluid and electrolyte abnormalities and use of critical care services may be some of the reasons for the discrepancy between data reported.

Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria

Clinical cure of the infection due to pandrug-resistant Gram-negative bacteria, namely Pseudomonas aeruginosa or Klebsiella pneumoniae was observed in 4 out of 6 patients with combination of colistin and beta lactam antibiotics.

New information about the polymyxin/colistin class of antibiotics

Improvements in dosing, alternative methods of administration and different synergic antimicrobial combinations have been proposed in recent literature, among other measures, to enhance the effectiveness of polymyxins.



Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis

Although seven of eight patients who received nebulized colistin showed clinical improvement, some patients also received other active antibiotics, and microbiological eradication was demonstrated in only four of the eight patients, the results of this limited study suggest that further studies examining the use of nebulization colist in the treatment of nosocomial pneumonia are merited.

Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients

The lack of a control group in the present study does not allow any definite conclusions to be drawn regarding the clinical effectiveness of colistin, but this drug has an acceptable safety profile and its use should be considered in severe infections with multiresistant Gram-negative bacilli.

Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.

  • A. LevinA. Barone S. Costa
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1999
Colistin may be a good therapeutic option for the treatment of severe infections caused by multidrug-resistant P. aeruginosa and A. baumannii.

Toxicity after prolonged (more than four weeks) administration of intravenous colistin

Serum creatinine, blood urea, liver function tests, symptoms and signs of neurotoxicity were the main outcomes studied and no serious toxicity was observed in this group of patients who received prolonged intravenous colistin.

Synergistic Activity of Colistin and Ceftazidime against Multiantibiotic-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model

Colistin is an older but novel antibiotic that fell into disfavor with clinicians some time ago yet still retains a very favorable antibacterial spectrum, especially for Pseudomonas and Acinetobacter spp.

Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients.

It was found that the microdilution method is a valid, rapid and cost effective alternative for the determination of polymyxin activity and resistance among common CF pathogens is not rare, thus underlining the necessity of accurate susceptibility testing.

Microbiological Activity and Clinical Efficacy of a Colistin and Rifampin Combination in Multidrug-Resistant Pseudomonas aeruginosa Infections

The microbiological and clinical observations suggest that the addition of rifampin to colistin may result in a synergistic bactericidal combination that may be useful in patients with infections caused by MDR P. aeruginosa which are difficult to cure.

Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic.

Colistin should be considered as a treatment option in critically ill patients with infection caused by multiresistant Gram-negative bacilli, especially in patients with a history of renal failure.

A reassessment of the in-vitro activity of colistin sulphomethate sodium.

The results show that colistin remains a useful antimicrobial agent against Gram-negative bacteria, particularly those strains which are resistant to more commonly used antibiotics.

Toxicity of Colistin in Cystic Fibrosis Patients

It appears that intravenous colistin can be considered for cystic fibrosis patients with strains of P. aeruginosa that are resistant to more commonly used antibiotics.